{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:40:49Z","timestamp":1794480049064,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"cara therapeutics","id":[{"id":"https:\/\/ror.org\/057w5q630","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease-associated pruritus (CKD-aP) is characterized by persistent itch that often leads to substantially impaired quality of life. The Worst Itching Intensity Numerical Rating Scale (WI-NRS) is a single-item patient-reported outcome measure in which patients indicate the intensity of the worst itching they experienced over the past 24\u00a0h. Here, we evaluated the content validity and psychometric properties of the WI-NRS and confirmed the threshold of meaningful change in hemodialysis patients with moderate-to-severe CKD-aP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Content validity interviews were conducted in 23 patients. Psychometric properties of the WI-NRS were assessed using data from one phase 2 (N\u2009=\u2009174) and two phase 3 (N\u2009=\u2009848) clinical trials investigating an anti-pruritic treatment. Anchor-based methods were used to confirm meaningful within-patient change score thresholds in the phase 3 trial patients and mixed-method exit interviews (N\u2009=\u200970) contributed further insight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Content validity interviews indicated patients considered the WI-NRS to be straightforward, comprehensive, and relevant. Test\u2013retest reliability was strong in both trial cohorts (intraclass correlation coefficients\u2009&gt;\u20090.75). Construct validity analyses indicated high correlation between the WI-NRS and other measures of itch. Anchor-based analyses showed a reduction of\u2009\u2265\u20093 points from baseline score represented an appropriate clinically meaningful within-patient change on the WI-NRS. In the exit interviews, all patients with a reduction\u2009\u2265\u20093 points considered the change meaningful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The WI-NRS is a reliable, valid, and responsive measure of itch intensity for patients with moderate-to-severe CKD-aP. These results support its use to assess treatment efficacy and in clinical evaluation and management of pruritus in hemodialysis patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-021-00404-z","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T15:02:22Z","timestamp":1640358142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus"],"prefix":"10.1186","volume":"5","author":[{"given":"Margaret K.","family":"Vernon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Swett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Speck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Munera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-1665","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"issue":"9","key":"404_CR1","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1038\/sj.ki.5000251","volume":"69","author":"I Narita","year":"2006","unstructured":"Narita I, Alchi B, Omori K et al (2006) Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69(9):1626\u20131632","journal-title":"Kidney Int"},{"issue":"3","key":"404_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/archderm.1982.01650150016012","volume":"118","author":"BA Gilchrest","year":"1982","unstructured":"Gilchrest BA, Stern RS, Steinman TI et al (1982) Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 118(3):154\u2013156","journal-title":"Arch Dermatol"},{"issue":"5","key":"404_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0190-9622(03)02478-2","volume":"49","author":"I Zucker","year":"2003","unstructured":"Zucker I, Yosipovitch G, David M et al (2003) Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 49(5):842\u2013846","journal-title":"J Am Acad Dermatol"},{"key":"404_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/IJNRD.S108045","volume":"10","author":"S Shirazian","year":"2017","unstructured":"Shirazian S, Aina O, Park Y et al (2017) Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis 10:11\u201326","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"3","key":"404_CR5","first-page":"157","volume":"5","author":"DR Kuypers","year":"2009","unstructured":"Kuypers DR (2009) Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 5(3):157\u2013170","journal-title":"Nat Clin Pract Nephrol"},{"issue":"4","key":"404_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ki.2013.454","volume":"87","author":"T Mettang","year":"2015","unstructured":"Mettang T, Kremer AE (2015) Uremic pruritus. Kidney Int 87(4):685\u2013691","journal-title":"Kidney Int"},{"issue":"12","key":"404_CR7","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","volume":"21","author":"RL Pisoni","year":"2006","unstructured":"Pisoni RL, Wikstr\u00f6m B, Elder SJ et al (2006) Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21(12):3495\u20133505","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"404_CR8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.2215\/CJN.00100110","volume":"5","author":"VS Mathur","year":"2010","unstructured":"Mathur VS, Lindberg J, Germain M et al (2010) A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 5(8):1410\u20131419","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"404_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2340\/00015555-2280","volume":"96","author":"K Hayani","year":"2016","unstructured":"Hayani K, Weiss M, Weisshaar E (2016) Clinical findings and provision of care in haemodialysis patients with chronic itch: new results from the german epidemiological haemodialysis itch study. Acta Derm Venereol 96(3):361\u2013366","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"404_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/00015550152384236","volume":"81","author":"G Yosipovitch","year":"2001","unstructured":"Yosipovitch G, Zucker I, Boner G et al (2001) A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 81(2):108\u2013111","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"404_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/jdv.15483","volume":"33","author":"N Plewig","year":"2019","unstructured":"Plewig N, Ofenloch R, Mettang T et al (2019) The course of chronic itch in hemodialysis patients: results of a 4-year follow-up study of GEHIS (German Epidemiological Hemodialysis Itch Study). J Eur Acad Dermatol Venereol 33(7):1429\u20131435","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"404_CR12","unstructured":"U.S. Food & Drug Administration. (2009). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims: Guidance for Industry. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. Accessed 27 July 2020."},{"issue":"4","key":"404_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaad.2020.06.991","volume":"84","author":"M Vernon","year":"2021","unstructured":"Vernon M, Stander S, Munera C et al (2021) Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus. J Am Acad Dermatol 84(4):1132\u20131134","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"404_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V et al (2019) Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 181(4):761\u2013769","journal-title":"Br J Dermatol"},{"issue":"2","key":"404_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/09546634.2014.906033","volume":"26","author":"CM Mamolo","year":"2015","unstructured":"Mamolo CM, Bushmakin AG, Cappelleri JC (2015) Application of the itch severity score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat 26(2):121\u2013123","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"404_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2340\/00015555-2856","volume":"98","author":"S St\u00e4nder","year":"2018","unstructured":"St\u00e4nder S, Luger T, Cappelleri JC et al (2018) Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis: results from a phase 3 tofacitinib program. Acta Derm Venereol 98(3):340\u2013345","journal-title":"Acta Derm Venereol"},{"key":"404_CR17","unstructured":"U.S. Food & Drug Administration. (2018). Patient-focused drug development: collecting comprehensive and representative input. guidance for industry, food and drug administration staff, and other stakeholders. https:\/\/www.fda.gov\/media\/139088\/download. Accessed 29 July 2020."},{"key":"404_CR18","unstructured":"U.S. Food & Drug Administration. (2018). Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments. https:\/\/www.fda.gov\/media\/116277\/download. Accessed 30 July 2020."},{"issue":"2","key":"404_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11136-004-0705-2","volume":"14","author":"KW Wyrwich","year":"2005","unstructured":"Wyrwich KW, Bullinger M, Aaronson N et al (2005) Estimating clinically significant differences in quality of life outcomes. Qual Life Res 14(2):285\u2013295","journal-title":"Qual Life Res"},{"key":"#cr-split#-404_CR20.1","unstructured":"Critical Path Institute. (2019). Using Patient Input to Estimate Clinically Meaningful Within-Patient Change at the Scale Score Level. Paper presented at: Tenth Annual Patient-Reported Outcome Consortium Workshopp"},{"key":"#cr-split#-404_CR20.2","unstructured":"April 24-25, 2019. https:\/\/c-path.org\/wp-content\/uploads\/2019\/05\/2019_session6_meaningfulchgfinal.pdf. Accessed 30 July 2020."},{"issue":"7","key":"404_CR21","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.jsxm.2018.04.012","volume":"15","author":"PE Koochaki","year":"2018","unstructured":"Koochaki PE, Revicki DA, Wilson H et al (2018) Bremelanotide provides meaningful treatment benefits for premenopausal women with hypoactive sexual desire disorder. J Sex Med 15(7):S126","journal-title":"J Sex Med"},{"issue":"1","key":"404_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L et al (2019) An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes 3(1):16","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"404_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","volume":"5","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Mathur V, Germain MJ et al (2020) Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep 5(5):600\u2013610","journal-title":"Kidney Int Rep"},{"issue":"3","key":"404_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1912770","volume":"382","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Jamal A, Munera C et al (2020) A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 382(3):222\u2013232","journal-title":"N Engl J Med"},{"key":"404_CR25","unstructured":"ClinicalTrials.gov. (2021). CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-2). NCT03636269. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03636269. Accessed 8 Jan 2021."},{"issue":"3","key":"404_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","volume":"162","author":"S Elman","year":"2010","unstructured":"Elman S, Hynan LS, Gabriel V et al (2010) The 5-D itch scale: a new measure of pruritus. Br J Dermatol 162(3):587\u2013593","journal-title":"Br J Dermatol"},{"key":"404_CR27","volume-title":"Measuring functioning and well-being","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart AL (1992) Sleep measures. In: Stewart AL, Ware JE (eds) Measuring functioning and well-being. Duke University Press, Durham"},{"key":"404_CR28","unstructured":"Guy W. (1976). ECDEU Assessment Manual for Psychopharmacology. US Department of Heath, Education, and Welfare, Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD."},{"issue":"2","key":"404_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420\u2013428","journal-title":"Psychol Bull"},{"issue":"3","key":"404_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1015291021312","volume":"11","author":"N Aaronson","year":"2002","unstructured":"Aaronson N, Alonso J, Burnam A et al (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11(3):193\u2013205","journal-title":"Qual Life Res"},{"issue":"1","key":"404_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","volume":"17","author":"CA Prinsen","year":"2016","unstructured":"Prinsen CA, Vohra S, Rose MR et al (2016) How to select outcome measurement instruments for outcomes included in a \u201cCore Outcome Set\u201d - a practical guideline. Trials 17(1):449","journal-title":"Trials"},{"key":"404_CR32","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale","edition":"2"},{"key":"404_CR33","unstructured":"Food and Drug Administration. (2019). Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. December 6, 2019. https:\/\/www.fda.gov\/media\/132505\/download. Accessed 12 Nov 2020."},{"issue":"1","key":"404_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12882-017-0475-z","volume":"18","author":"JW Lai","year":"2017","unstructured":"Lai JW, Chen HC, Chou CY et al (2017) Transformation of 5-D itch scale and numerical rating scale in chronic hemodialysis patients. BMC Nephrol 18(1):56","journal-title":"BMC Nephrol"},{"issue":"5","key":"404_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F et al (2012) Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 92(5):502\u2013507","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"404_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2340\/00015555-1265","volume":"92","author":"A Reich","year":"2012","unstructured":"Reich A, Heisig M, Phan NQ et al (2012) Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 92(5):497\u2013501","journal-title":"Acta Derm Venereol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-021-00404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-021-00404-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-021-00404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T15:07:46Z","timestamp":1640358466000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-021-00404-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1186\/s41687-021-00404-z","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Interview study protocols were approved by an Institutional Review Board (Advarra Inc., MD, US) and recruitment procedures complied with Health Insurance Portability and Accountability Act regulations. All participants provided their written informed consent prior to interviews and were remunerated upon interview completion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MKV is employed by Evidera. LLS and RMS were employed by Evidera at the time this work was completed. FM, CM, WW, and RHS are employed by Cara Therapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}